President And Fellows Of Harvard College

President and Fellows of Harvard College, operating through Harvard Medical School's Office of Research Administration Division, functions as a federal research recipient and prime contractor delivering biomedical research, clinical training, and laboratory services to the federal government, with 91% of recent awards as prime (2,311 of 2,531 awards). Harvard Medical School is a tax-exempt nonprofit academic medical research institution and does not compete under SBA set-asides; it operates as a full-and-open competitor in federal research funding, particularly through NIH grant programs and federal research contracts.

Harvard Medical School's federal footprint centers on biomedical research and laboratory services. The institution serves as a recipient on federal grant programs, notably the National Institutes of Health's grant portfolio across multiple institutes and centers. Recent representative prime grant awards include a $1.999 billion project grant from NIAID (September 2026) supporting the ImmGen Consortium's dissection of gene expression and regulation across immune system cell lineages through shared data generation pipelines and spatial transcriptomics, a $802.750 million project grant from NIH's Office of the Director (September 2026) for organelle-theft research in sea slugs studying chloroplast integration into animal cells, and a $1.678 billion project grant from the National Human Genome Research Institute (May 2026) to leverage ancient DNA across 34,000 West Eurasians to elucidate genetic architecture of complex human traits. The institution also holds prime federal contracts. A $4.399 million Other Transaction Agreement with the National Institutes of Health (July 2026, HARVARD - PROPEL, completion July 2027) operates outside the FAR under alternative transaction authority. A $319,998 firm fixed-price definitive contract with Veterans Integrated Service Network 10 (April 2026, completion April 2028) engages Harvard Medical School subject matter experts to adapt proprietary claims-based quality measures into VA-compatible data formats, awarded on a sole-source basis under FAR 6.103-1 for services identified as unavailable from other known vendors. Harvard Medical School has also received firm fixed-price purchase orders from the National Institute on Aging for laboratory testing (nascent transcript analysis in B cells, $16,139, February 2026, completion May 2026) and from a federal agency's Northeast Area office for proteome analysis via mass spectrometry on soybean samples ($16,000, August 2024, completion October 2024).

Customer concentration is heavily weighted to NIH. The top funding customer, Department of Health and Human Services National Institutes of Health, accounts for 723 awards (28% of the total award count, 55% of awards from top-five customers), followed by NIAID (198 awards), National Institute of General Medical Sciences (164 awards), National Institute of Neurological Disorders and Stroke (154 awards), and National Cancer Institute (153 awards). DARPA ranks as the top customer by potential value, with 22 awards valued at $33.5 million combined, while NIDA carries 30 awards worth $7.1 million. This split reveals a characteristic portfolio: NIH dominates by volume of awards (grant programs), while DARPA carries the largest potential-value concentration in contracts. The institution serves 86 distinct federal agencies, indicating broad federal market exposure.

Harvard Medical School does not operate under parent contract vehicles (GWACs, IDIQs) in the traditional sense. Recent vehicles showing task-order activity include an Indefinite Delivery Contract (HHSM500200600015I) with three task orders, a Multiple Award Schedule with two task orders, and a VA IDC (VA24113D0088) with two task orders valued at $30 thousand. These vehicles represent a minimal share of the overall award portfolio and reflect the institution's primary operation as a direct research recipient rather than a vehicle-seated contractor.

Activity has remained stable to modestly declining. Awards per year ran at 121 (2023), 138 (2024), 117 (2025), and 96 (2026), with 16 awards through March 2027. Combined potential value across all awards totals $85.8 million, but obligated dollars across all awards stand at $5.22 billion, indicating substantial prior-year commitments and invoicing against multi-year awards. Two hundred nine awards face completion within the next twenty-four months, carrying $10.9 million in combined potential value—a moderate recompete window typical of NIH's rolling grant-renewal cycle.

Service Contract Inventory reporting captures a narrow slice of Harvard Medical School's federal activity. SCI-reportable invoiced revenue across prime service contracts totaled $4.2 million (FY2023–FY2025), with $269 thousand in FY2023 (0.7 FTEs), $2.4 million in FY2024 (6.4 FTEs), and $1.6 million in FY2025 (4.7 FTEs). These SCI-reported figures exclude grant revenue, goods purchases, and the institution's broader research portfolio, and represent only federal service contracts above the $150,000 reporting threshold. Government-paid hourly rates on SCI-reportable prime service contracts ranged from a tenth-percentile $165.62/hr to a median $184.90/hr to a ninetieth-percentile $223.20/hr, positioning the institution at academic-research labor rates. Across SCI-reportable prime contracts, subcontractors performed roughly 10% of total contractor hours (11 named subcontractors reported), indicating Harvard Medical School typically delivers the majority of service work using internal resources, with subs playing a modest supporting role.

Harvard Medical School operates as a prime on 91% of recent awards and as a named subcontractor on grants and contracts to other research institutions and federal prime recipients (such as Duke University, Brigham & Women's Hospital, and the Children's Hospital Corporation). Recent sub-award roles include sequencing support for olfactory epithelium samples to Duke University (September 2026), immunologic analyses of T cell responses to Brigham & Women's Hospital investigating immune checkpoint timing (September 2026), and collaboration with University of Pittsburgh on single-cell spatial proteotranscriptomics of pancreatic neuroendocrine tumors. The sub-awards reflect the institution's positioning as a specialized research capability drawn in by other research organizations as a collaborating expert unit rather than as a routine materials or services vendor. Top NAICS categories reflect this research focus: Colleges, Universities, and Professional Schools (30 awards), Research and Development in Life Sciences (12 awards), Testing Laboratories and Services (8 awards).

Parent vendor President and Fellows of Harvard College operates the institution as a tax-exempt corporate entity. Harvard Medical School operates as the research and academic medical division, headquartered at Gordon Hall, 25 Shattuck Street, Boston, Massachusetts 02115.